Kairos Pharma completes safety lead-in of ENV105 trial

Kairos Pharma (KAPA) announced the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial began with the safety lead-in, which combined apalutamide, a standard of care for prostate cancer, with the company’s compound ENV105. The second part of the study, which randomizes patients to receive either apalutamide alone or in combination with ENV105 is ongoing. The company expects to announce the safety and efficacy data readout from the safety arm of the trial beginning in the first half of 2025.